8-K: Perrigo Reaffirms FY25 EPS Amid Sales Headwinds

Perrigo Company plc reported mixed second-quarter 2025 results, reaffirming its full-year adjusted EPS target despite net sales trending towards the lower end of guidance due to challenging market conditions and slower infant formula recovery.

Summary

• Net sales for Q2 2025 were $1.06 billion, a 0.9% decrease year-over-year, with organic net sales declining 0.1%.
• Adjusted diluted EPS for Q2 2025 increased by 7.5% to $0.57, or 12.5% organically, driven by lower interest expense.
• Reported operating income improved significantly to $45 million in Q2 2025 from a loss of $27 million in the prior year.
• Adjusted operating income for Q2 2025 was $135 million, down 2.9%, primarily due to production variability in infant formula and lower plant overhead absorption.
• First half 2025 net sales were $2.10 billion, down 2.2% year-over-year, with organic net sales declining 0.3%.
• First half 2025 adjusted EPS increased 41.0% to $1.17, or 53.3% organically.
• Year-to-date operating cash flow was $11 million, with cash and cash equivalents at $454 million and total debt at $3.65 billion as of June 28, 2025.
• The company reaffirmed its full-year 2025 financial targets, including adjusted EPS of $2.90 to $3.10, but expects reported and organic net sales growth to be at the lower end of their respective ranges (0-3% and 1.5-4.5%).
• Perrigo OTC store brands gained unit and volume share during the quarter.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While net sales are challenged and infant formula recovery is slower than expected, the company successfully improved reported operating income, grew adjusted EPS, and reaffirmed its full-year earnings outlook. Strategic initiatives like Project Energize are yielding benefits, and the planned divestiture of Dermacosmetics is a positive step for the balance sheet. However, ongoing macroeconomic headwinds and specific category declines temper the overall optimism.

Positives

• Adjusted diluted EPS increased by 7.5% to $0.57 in Q2 2025 and by 41.0% to $1.17 in H1 2025, driven by lower interest expense and operating efficiencies.
• Reported operating income significantly improved from a loss of $27 million in Q2 2024 to a gain of $45 million in Q2 2025.
• The company's 'Three-S' strategic plan (Stabilize, Streamline, and Strengthen) is advancing, with benefits from Project Energize and Supply Chain Reinvention.
• Project Energize has achieved gross annual savings of approximately $159 million since its inception in 2024.
• The agreement to sell the Dermacosmetics business is expected to strengthen the balance sheet and accelerate net leverage goals.
• Perrigo's diversified portfolio and upgraded brand building capabilities are generating positive results, with store brands and key brands gaining market share.
• The Nutrition category, particularly infant formula, showed continued recovery and growth in both Q2 and H1 2025.
• CSCI segment achieved organic net sales growth of 2.7% in Q2 2025 and 3.6% in H1 2025, driven by Pain & Sleep Aids and Upper Respiratory categories.

Negatives

• Net sales declined 0.9% in Q2 2025 and 2.2% in H1 2025, with organic net sales also showing slight declines.
• Adjusted operating income decreased by 2.9% in Q2 2025, reflecting isolated production variability in infant formula leading to increased product scrap.
• Lower plant overhead absorption in OTC and Oral Care segments negatively impacted gross profit.
• The impact of divestitures and exited products unfavorably affected net sales, gross profit, and operating income.
• Challenging consumer environments in the U.S. and EU, along with soft seasonal consumption trends in certain segments like allergy, sun care, and blister care, impacted performance.
• Recovery in the infant formula business is slower than anticipated, contributing to net sales expectations being at the lower end of the guidance range.
• Declines in Digestive Health (due to lower consumption of specific molecules) and Oral Care (due to lost distribution of lower-margin products) in the CSCA segment.
• The absence of prior-year Opill launch stocking benefit and lost distribution of lower-margin U.S. store brand products negatively impacted H1 organic net sales.
• Expected gross increase to global cost of goods sold of approximately $10 million to $20 million starting Q4 2025, and $50 million to $60 million on a full-year basis, due to global tariffs.

Risks

• Ability to complete the proposed divestment of the Dermacosmetics branded business, including receipt of works council and regulatory approval, counterparty performance, and satisfaction of deferred payment milestones.
• Supply chain impacts, including those caused or exacerbated by armed conflict, trade and other economic sanctions, and/or disease.
• General economic, credit, and market conditions.
• Increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs) and changes in global trade relations.
• The impact of the war in Ukraine and any escalation thereof, including economic and political sanctions.
• Outbreak or escalation of conflict in other regions where the company does business, including the Middle East.
• Current and future impairment charges if the carrying amount of specific assets may not be recoverable.
• Customer acceptance of new products and competition from other industry participants with greater marketing resources or larger market shares.
• Pricing pressures from customers and consumers.
• Resolution of uncertain tax positions and any litigation relating thereto, as well as ongoing or future government investigations and regulatory initiatives.
• Uncertainty regarding the ability to obtain and maintain regulatory approvals.
• Potential costs and reputational impact of product recalls or sales halts.
• Potential adverse changes to U.S. and foreign tax, healthcare, and other government policy.
• Fluctuations in currency exchange rates and interest rates.
• The ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including ongoing restructuring programs.
• Adverse results with respect to pending litigation could have a material adverse impact on operating results, cash flows, and liquidity.

Future Outlook

Perrigo reaffirms its full-year 2025 financial targets, including an adjusted diluted EPS range of $2.90 to $3.10, representing 13% to 21% growth. However, reported and organic net sales growth are expected to be towards the lower end of their respective ranges (0-3% and 1.5-4.5%), primarily due to infant formula industry dynamics and challenging market consumption trends. The company anticipates an approximate 40% adjusted gross margin, 15% adjusted operating margin, 100% operating cash flow conversion to adjusted net income, and 6% free cash flow as a percentage of net sales. Net leverage is targeted at approximately 3.5x adjusted EBITDA.

Management Comments

• President and CEO Patrick Lockwood-Taylor stated, "Our second quarter results reflect the continued execution by the global Perrigo team against our 'Three-S strategic plan. Despite a challenging consumer environment in the U.S. and EU, our diversified portfolio—spanning more molecules at more price points—continues to provide resilience and stability."
• Lockwood-Taylor also noted, "Our upgraded brand building capabilities are generating positive results as our store brands and key brands are gaining share in their respective markets—demonstrating the strength of our diversified business even amid soft seasonal consumption trends in certain segments, such as allergy, sun care and blister care."
• Regarding future plans, Lockwood-Taylor commented, "The previously announced sale of our Dermacosmetics business, which is expected to close in the first quarter of 2026, sharpens our organizational focus. Expected net proceeds from this transaction will be prioritized towards strengthening our balance sheet and accelerating our net leverage goals."
• Lockwood-Taylor acknowledged challenges, stating, "While recovery in our infant formula business continues, it is slower than anticipated. This, coupled with challenging market consumption, has led to our expectations for 2025 topline growth to be towards the lower ends of our previously stated ranges."
• Despite the challenges, Lockwood-Taylor expressed confidence: "However, our share gains, operating discipline and cost efficiencies are enabling us to reaffirm our full-year earnings outlook. Our unique offerings continue to support agile execution in a dynamic environment, and we remain confident in Perrigo’s ability to drive sustainable growth and create long-term value for shareholders."

Industry Context

The company operates within a challenging consumer environment in both the U.S. and EU, experiencing soft seasonal consumption trends in certain categories like allergy, sun care, and blister care. The infant formula market's recovery is slower than anticipated, impacting top-line growth. Perrigo's business model, characterized by a diversified portfolio of over 100 molecules across all price points and significant U.S.-based manufacturing (85% of finished goods), is positioned to offer resilience. The company believes its store brand and value brand offerings may benefit from shifting consumer behavior towards more affordable options as consumer prices rise. Global tariffs are expected to increase the cost of goods sold, a trend impacting the broader industry.

Comparison to Industry Standards

• The filing states that non-GAAP financial measures are provided to facilitate comparability with companies in similar industries and to assist in comparing the company's overall performance to that of its competitors and peer business group.
• However, the filing does not provide specific comparable companies, projects, or detailed industry benchmarks against which Perrigo's results can be directly assessed.

Legal Proceedings

• The company incurred charges related to 'unusual litigation' in both Q2 2025 and H1 2025, which were excluded from non-GAAP adjustments.
• Cash outflow in Q1 2025 was partly driven by cash utilized to settle outstanding litigation.
• The company acknowledges the risk that adverse results with respect to pending litigation could have a material adverse impact on its operating results, cash flows, and liquidity.

Stakeholder Impact

• Shareholders: Reaffirmed adjusted EPS outlook provides stability, while the Dermacosmetics divestiture aims to strengthen the balance sheet and accelerate net leverage goals, potentially creating long-term value.
• Customers/Consumers: Perrigo's diversified portfolio and focus on store brands and value offerings may benefit consumers seeking more affordable self-care solutions amidst rising prices.
• Employees: Project Energize, a global investment and efficiency program, involves restructuring charges, which may imply organizational changes and potential impacts on employees.
• Creditors: The planned divestiture and focus on strengthening the balance sheet and accelerating net leverage goals are positive for creditors.

Next Steps

• The company will host an earnings conference call on August 6, 2025, to discuss the financial results.
• The sale of the Dermacosmetics business is expected to close in the first quarter of 2026.
• Project Energize is expected to produce significant benefits and deliver annualized pre-tax savings in the range of $140 million to $170 million by the end of 2026.
• The company plans to offset the impact of global tariffs through a combination of strategic pricing actions, insourcing to U.S.-based manufacturing facilities, and other supply chain actions.

Key Dates

Recommendation

Perrigo's Q2 2025 results present a mixed picture. While the company successfully improved reported operating income and delivered adjusted EPS growth, it faces ongoing challenges with declining net sales and a slower-than-anticipated recovery in its infant formula business. The reaffirmation of the full-year adjusted EPS target is a positive signal of management's confidence in cost efficiencies and strategic initiatives like Project Energize. The planned divestiture of the Dermacosmetics business is a strategic move to streamline focus and strengthen the balance sheet. However, macroeconomic headwinds, including tariffs and a challenging consumer environment, introduce uncertainty. Given the balance of strategic progress and operational challenges, a 'hold' recommendation is appropriate, allowing investors to observe the execution of the 'Three-S' plan and the impact of mitigation strategies on top-line growth and profitability.

Keywords

Perrigo, PRGO, Consumer Self-Care, OTC, Infant Formula, Earnings, Financial Results, Adjusted EPS, Net Sales, Operating Income, Project Energize, Dermacosmetics, Divestiture, Supply Chain, Tariffs, Healthcare, Pharmaceuticals, Store Brands, Private Label